Skip to main content

Videos

Exploring Prognostic Determinants in Patients With mCRC

Exploring Prognostic Determinants in Patients With mCRC

FEATURING:

Pashtoon Kasi, MD, MS

August 15, 2023

Rapid Reactions

Older Patients With Metastatic Colorectal Cancer: Real-World Experience in the US

Older Patients With Metastatic Colorectal Cancer: Real-World Experience in the US

FEATURING:

Pashtoon Kasi, MD, MS

August 8, 2023

Rapid Reactions

Sagar D. Sardesai, MBBS, on the Approval of ORSERDU™

Sagar D. Sardesai, MBBS, on the Approval of ORSERDU™

FEATURING:

Sagar D. Sardesai, MBBS

August 1, 2023

Interview with the Innovators

Targeted Therapy Investigations: Study Outcomes and Designs in mCRC

Targeted Therapy Investigations: Study Outcomes and Designs in mCRC

FEATURING:

Pashtoon Kasi, MD, MS

July 26, 2023

Rapid Reactions

Biomarker Testing in mCRC to Help Identify Appropriate Patients for Targeted Treatment

Biomarker Testing in mCRC to Help Identify Appropriate Patients for Targeted Treatment

FEATURING:

Pashtoon Kasi, MD, MS

July 18, 2023

Rapid Reactions

Chaitali Nangia, MD, on the Approval of ORSERDU™

Chaitali Nangia, MD, on the Approval of ORSERDU™

FEATURING:

Chaitali Nangia, MD

July 3, 2023

Interview with the Innovators

Yuan Yuan, MD, PhD, on the Approval of ORSERDU™

Yuan Yuan, MD, PhD, on the Approval of ORSERDU™

FEATURING:

Yuan Yuan, MD, PhD

June 6, 2023

Interview with the Innovators

$Relapsed or Refractory FL: Best Practices for Active Surveillance & Reinforcement of Management Plans$

Relapsed or Refractory FL: Best Practices for Active Surveillance & Reinforcement of Management Plans

FEATURING:

Tycel J. Phillips, MD; Peg Rummel, MHA, RN, OCN, NE-BC; Andrew D. Zelenetz, MD, PhD

October 4, 2022

Interview with the Innovators

Updates on 1L Maintenance Therapy with PARP Inhibitors for Advanced Ovarian Cancer

Updates on 1L Maintenance Therapy with PARP Inhibitors for Advanced Ovarian Cancer

FEATURING:

David O’Malley, MD

October 3, 2022

Rapid Reactions

Page 5 of 20